Safety and Efficacy of Treatment with Once-Daily Ledipasvir/Sofosbuvir (90/400 mg) for 12 Weeks in Genotype 1 HCV-Infected Patients with Severe Renal Impairment

被引：0

作者：

Lawitz, Eric ^{[2
]}

Landis, Charles S. ^{[3
]}

Maliakkal, Benedict J. ^{[4
]}

Bonacini, Maurizio ^{[5
]}

Ortiz-Lasanta, Grisell ^{[6
]}

Zhang, Jie ^{[1
]}

Mogalian, Erik ^{[1
]}

De-Oertel, Shampa ^{[1
]}

Osinusi, Anu O. ^{[1
]}

Brainard, Diana M. ^{[1
]}

McHutchison, John G. ^{[1
]}

Flamm, Steven L. ^{[7
]}

Gordon, Stuart C. ^{[8
]}

Gane, Edward J. ^{[9
]}

机构：

[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[2] Univ Texas Hlth, Texas Liver Inst, San Antonio, TX USA

[3] Univ Washington, Med Ctr, Seattle, WA 98195 USA

[4] Univ Tennessee, Memphis, TN USA

[5] Univ Calif San Francisco, Mission Gastroenterol & Hepatol, San Francisco, CA 94143 USA

[6] Fdn Invest Diego, San Juan, PR USA

[7] Northwestern Univ, Div Gastroenterol & Hepatol, Chicago, IL 60611 USA

[8] Henry Ford Hlth Syst, Detroit, MI USA

[9] Auckland Clin Studies, Auckland, New Zealand

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1587

引用

页码：848A / 848A

页数：1